FT商学院

Chinese IPOs in US falter amid scrutiny of manipulation schemes

Regulators crack down after trading in ‘toxic’ small-cap stocks from China inflicted losses on US investors

Chinese company listings on US stock exchanges have ground to a halt after a two-year boom as regulators in both countries step up scrutiny because of concerns over stock manipulation.

Just two Chinese companies have listed in New York since the start of January, compared with 19 in the same period last year, according to an FT analysis of public records. A record 126 Chinese initial public offerings occurred across 2024 and 2025.

The freeze follows months of tighter scrutiny by China’s securities regulator of offshore listings by domestic companies, with no new approvals granted since December. Nasdaq has also tightened listing standards, including by raising minimum fundraising thresholds and broadened its discretion to delay or deny IPOs it believes could be vulnerable to manipulation.

您已阅读16%(797字),剩余84%(4316字)包含更多重要信息,订阅以继续探索完整内容,并享受更多专属服务。
版权声明:本文版权归manbetx20客户端下载 所有,未经允许任何单位或个人不得转载,复制或以任何其他方式使用本文全部或部分,侵权必究。
设置字号×
最小
较小
默认
较大
最大
分享×